DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

ULTRAGENYX PHARMAC (NASDAQ: RARE)

58.10 0.10 (0.17%)

Quote as of


company name or ticker

Recent Quotes

RARE $58.10 0.17%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.55
Previous Close $58.00
Daily Range $57.25 - $59.00
52-Week Range $32.02 - $69.77
Market Cap $1.9B
P/E Ratio -8.41
Dividend (Yield) $0.00 (0.0%)
Volume 243,825
Average Daily Volume 322,815
Current FY EPS -$2.24

Sector

Industry

ULTRAGENYX PHARMAC (RARE) Description

ULTRAGENYX PHARMAC Website: http://www.ultragenyx.com/

News & Commentary Rss Feed

Why Ultragenyx Pharmaceutical Inc. Stock Slumped

Ultragenyx shares aren't looking so "ultra" today after the company announced its intention to sell shares of common stock. Find out what this means for investors.

Monday's ETF Movers: XBI, RYT

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteo

Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog

Ultragenyx Pharma Offers Interim Data from Phase 3 Extension Study of Sialic Acid ER at Int'l Congre

Ultragenyx Pharma Offers Interim Data from Phase 3 Extension Study of Sialic Acid ER at Int'l Congress of World Muscle Safety

Benzinga's Top Initiations

3 Partnerships Pushing The Pharmaceutical Sector Forward

Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients Wi

Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia

US IPO Pricing Recap: ReWalk runs - year's 5th IPO to top 100% in first-day trading

Ultragenyx Offers Positive Interim Data from Phase 1/2 Study of Recombinant Human Beta-Glucuronidase

See More RARE News...